Not logged in...
About USC Norris
FAQ - Trials
Contact Us - Trials
Support USC Norris
» Contact Us
If you are a patient, please contact
The Doctors of USC
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High-Risk Multiple Myeloma (HRMM).
Open to Accrual
Anti-Angiogenesis, Chemotherapy: Systemic, Immunomodulator, Immunotherapy
Defintions of terms and FAQ about clinical trials.
Sikander Ailawadhi, M.D.
Other Trial Staff:
Christine Duran, D.M., Teh-Chun Wang, R.N.
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.